Trial Profile

A Phase III, Open-Label, Randomised Study to Assess the Efficacy and Safety of Extended Therapy With Camizestrant Versus Standard Endocrine Therapy (Aromatase Inhibitor or Tamoxifen) in Patients With ER+/HER2- Early Breast Cancer

Status: Recruiting

Phase of Trial: Phase III

Latest Information Update: 21 May 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Camizestrant (Primary) ; Anastrozole; Exemestane; Letrozole; Tamoxifen
Indications Early breast cancer; HER2 negative breast cancer; Male breast cancer
Focus Registrational; Therapeutic Use
Acronyms CAMBRIA-1
Sponsors AstraZeneca

11 Feb 2025 Planned primary completion date changed from 19 Apr 2027 to 20 Apr 2027.
24 Oct 2023 Trial design,presented at the 48th European Society for Medical Oncology Congress
10 Oct 2023 Planned primary completion date changed from 16 Apr 2027 to 19 Apr 2027.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com